Skip to content

Supplier News

Schweppes rolls out dark ginger ale

Schweppes rolls out dark ginger ale

With the onset of the holiday season, Schweppes has introduced the new Schweppes Dark Ginger Ale to give consumers more ginger taste. The Dr. Pepper Snapple Group brand said Monday that Schweppes Dark Ginger Ale taps into the rising demand for stronger flavors.

EcoTools unveils holiday brush sets

EcoTools unveils holiday brush sets

EcoTools is featuring three limited-edition holiday makeup brush sets in a new online videos as part of its “Looks You Love” series. The beauty care accessories company said Monday that the video tutorials introduce new makeup and hair looks for the holidays developed by the EcoTools Beauty Team.

BIOTA Botanicals launches new website

BIOTA Botanicals launches new website

BIOTA Botanicals has launched a new website for its U.S. customers, BiotaUSA.com. Content on the new site spotlights the BIOTA Botanicals Advanced Herbal Care and BIOTA Botanicals Proactive Herbal Care brands, hair care tips and where-to-buy information.

Keurig Green Mountain to go private in buyout

Keurig Green Mountain to go private in buyout

Keurig Green Mountain Inc. is slated to go private in a $13.9 billion buyout deal by a JAB Holding Co.-led investor group. The companies said Monday that the investor group plans to acquire Keurig Green Mountain for $92 per share in cash, which represents a premium of 77.9% over the coffee giant’s

Heritage releases Calan generic

Heritage releases Calan generic

Heritage Pharmaceuticals Inc. has rolled verapamil 40-mg immediate-release tablets, a calcium channel blocker medication. Heritage said that its verapamil product is a generic version of Pfizer Inc.’s Calan, indicated for the treatment of angina, arrhythmias and hypertension.

PharmaSmart, Astrup Drug partner in BP pilot

PharmaSmart, Astrup Drug partner in BP pilot

Blood pressure kiosk maker PharmaSmart took part in a pilot with Astrup Drug’s Sterling Pharmacy and nonprofit health group HealthPartners to show the potential of community pharmacists in helping patients with hypertension.

Pfizer to acquire Allergan for $160 billion

Pfizer to acquire Allergan for $160 billion

Pfizer Inc. plans to acquire Allergan Inc. for about $160 billion in the biggest deal ever in the health care sector. Pfizer said Monday that the transaction will allow the New York-based drug giant to relocate to Ireland to cut its U.S. tax burden. “The proposed combination of Pfizer

AmerisourceBergen’s Collis to become chairman

AmerisourceBergen’s Collis to become chairman

Steven Collis, president and chief executive officer of AmerisourceBergen Corp., has been named to succeed Richard Gozon as chairman. The company said Wednesday that Collis is slated to become chairman upon Gozon’s retirement at AmerisourceBergen’s annual shareholders meeting on March 3, 2016.

Global drug spending to climb steadily

Global drug spending to climb steadily

More than half of the world’s population will live in countries where medicine use will exceed one dose per person per day by 2020, up from 31% a decade ago, as the “medicine use gap” between developed and pharmerging markets narrows, the IMS Institute for Healthcare Informatics projects.

Perrigo shareholders nix Mylan bid

Perrigo shareholders nix Mylan bid

Shareholders of Perrigo Co. plc have rejected a hostile bid by Mylan N.V. to acquire the company in a deal valued at about $27 billion. Perrigo said Friday that shareholders holding more than 60% of its outstanding shares declined to tender into Mylan’s offer by the 8 a.m. ET deadline. The offer

AB InBev, SABMiller strike deal to merge

AB InBev, SABMiller strike deal to merge

Beer giants Anheuser-Busch InBev has reached an agreement to acquire SABMiller plc in a deal valued at about $108 billion. Clearing the way for the agreement was a deal for SABMiller to sell its 58% stake in its MillerCoors LLC joint venture to partner Molson Coors Brewing Co. for $12 billion.

N.J. governor signs biosimilars legislation

N.J. governor signs biosimilars legislation

New Jersey Gov. Chris Christie has approved legislation to create a pathway for the substitution of interchangeable biologic drugs, drawing praise from the Biotechnology Industry Organization (BIO) and BioNJ, a state biotechnology organization.